Zacks Investment Research reports that OraSure Technologies, Inc. (NASDAQ:$OSUR) is expected to post sales of $40.82 for the current quarter. This is based on two expert estimates that range from $40.50 million to $41.4 million. In the same quarter last year, OraSure Technologies posted sales of $32.25 million, suggesting a growth of 26.6% year over year. On Wednesday, November 1st the company will officially release its next quarterly earnings report.
OraSure is a medical diagnostic tool supplier who develops diagnostic devices and tests that can use patient’s saliva to detect various illnesses. Their products include tests for HIV and drug use. They sell to a wide range of customers that includes clinical laboratories, hospitals, community centers, schools, workplaces, and direct customers.
Reports of $40.82 full year sales are expected from the company in the current financial year. Estimates range from $153.50 million to $154.88 million. Future forecasts indicate sales of $171.47 million per share with a range of estimates from $170.00 million to $172.95, based on Zacks’ survey of sell-side analytics.
On Tuesday, OraSure’s stock opened at $22.14. They currently have a market cap of $1.32 billion. They also have a 50 and 200-day moving average of $20.72 and $16.18. Its beta sts at 1.57, making it roughly 50% more volatile than the market average.
A number of analysts have weighed in on the stock recently:
- Canaccord Genuity, in a report on June 28th, gave the company a ‘Buy’ rating and increased their target price from $15.00 to $18.00.
- Jefferies Group LLC, also on June 28th, gave the company a ‘Buy’ rating and moved its target price to $19.00 from $16.00.
- Stephens, on July 11th, gave the company an ‘Overweight’ rating and increased its target price from $14.00 to $19.00.
- BidaskClub, on July 24th, dropped their rating from ‘Strong-Buy’ to ‘Buy’.
- Zacks Investment Research, in a research not on September 8th, dropped their rating from ‘Buy’ to ‘Hold’.
The company received 6 ‘Buy’ ratings and 1 ‘Hold’ rating, with a consensus target price of $18.04.
In insider news, Anthony Zezzo II, the company’s EVP, sold 73,916 shares at an average price of $21.26 for a total transaction of $1,550,194.16. The deal took place on August 7th and the EVP now owns 218,326 shares in the company valued at $4,641,610.76. In addition, Jack E. Jerrett, SVP, sold 73.463 and an average price of $20.77 for a total value of $1,526,826.51 on August 7th. Jerrett currently owns 82,593 shares worth a total of $1,694,686.61. Insider ownership accounts for 6.40% of ownership.
Featured Image: twitter
